Iqbal Ike K. Ahmed
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Iqbal Ike K. Ahmed has a total of 250 co-authors. Here are the top co-authors by number of shared publications:
Matthew B. Schlenker
23 shared publications- Ticiana De Francesco
John A. Moran Eye Center, University of Utah, Salt Lake City, UT, USA
10 shared publications Harmanjit Singh
Department of Ophthalmology and Vision Sciences, University of Toronto, Toronto
5 shared publications- Marko M. Popovic
Department of Ophthalmology and Vision Sciences, University of Toronto, Toronto, Ontario, Canada
5 shared publications Xavier Campos-Möller
Prism Eye Institute, Mississauga, Canada; Western Health Eye Care Center, Corner Brook, Newfoundland, Canada
5 shared publicationsAmer F. Alsoudi
Cullen Eye Institute, Baylor College of Medicine, Houston, TX, USA
4 shared publications
Latest Publications
- 13 November 2026
- Published by Wolters Kluwer Health in Journal of Cataract & Refractive Surgery
12-month visual and safety outcomes of the ELIOS procedure with cataract surgery in primary open-angle glaucoma
Purpose: To characterize early safety and visual outcomes through 12 months following combined phacoemulsification and ELIOS excimer laser trabeculostomy procedure in patients with mild-to-moderate primary open-angle glaucoma (POAG). Setting: Conducted at 20 US sites. Design: Prospective, multicenter, non-randomized clinical trial (NCT04899063). Methods: Adults aged ≥45 years with cataract and mild-to-moderate POAG underwent phacoemulsification with intraocular lens implantation followed immediately by the ELIOS procedure. Corrected distance visual acuity (CDVA), pachymetry, endothelial cell density (ECD), visual field measurements, and adverse events (AEs) were reported up to 12 months. Results: A total of 318 patients underwent the procedure; mean±SD age was 70.3±7.3 years, 172 (54.1%) were female, and 263 (82.7%) were White. Five intraoperative AEs were reported during cataract procedure and none during ELIOS procedure. Visual recovery was rapid and sustained: at month 12, all patients achieved CDVA 20/40 or better; CDVA was 2 and −9.10%, respectively. Through 12 months, 73 postoperative ocular AEs were reported in 17.3% of patients; the most common AEs were anterior chamber cell/flare requiring increased or reinitiated steroid therapy (5.7%), and worsening of visual field mean deviation by ≥2.5 dB from baseline (4.4%). Conclusions: Combined phacoemulsification-ELIOS was associated with a safety profile consistent with published outcomes following phacoemulsification alone, with predominantly early, self-limited postoperative events.
- 13 November 2026
- Published by Wolters Kluwer Health in Journal of Cataract & Refractive Surgery
12-month visual and safety outcomes of the ELIOS procedure with cataract surgery in primary open-angle glaucoma
Purpose: To characterize early safety and visual outcomes through 12 months following combined phacoemulsification and ELIOS excimer laser trabeculostomy procedure in patients with mild-to-moderate primary open-angle glaucoma (POAG). Setting: Conducted at 20 US sites. Design: Prospective, multicenter, non-randomized clinical trial (NCT04899063). Methods: Adults aged ≥45 years with cataract and mild-to-moderate POAG underwent phacoemulsification with intraocular lens implantation followed immediately by the ELIOS procedure. Corrected distance visual acuity (CDVA), pachymetry, endothelial cell density (ECD), visual field measurements, and adverse events (AEs) were reported up to 12 months. Results: A total of 318 patients underwent the procedure; mean±SD age was 70.3±7.3 years, 172 (54.1%) were female, and 263 (82.7%) were White. Five intraoperative AEs were reported during cataract procedure and none during ELIOS procedure. Visual recovery was rapid and sustained: at month 12, all patients achieved CDVA 20/40 or better; CDVA was 2 and −9.10%, respectively. Through 12 months, 73 postoperative ocular AEs were reported in 17.3% of patients; the most common AEs were anterior chamber cell/flare requiring increased or reinitiated steroid therapy (5.7%), and worsening of visual field mean deviation by ≥2.5 dB from baseline (4.4%). Conclusions: Combined phacoemulsification-ELIOS was associated with a safety profile consistent with published outcomes following phacoemulsification alone, with predominantly early, self-limited postoperative events.
- Open Access
- 7 September 2026
- Published by Elsevier in Canadian Journal of Ophthalmology
- Vol. 61 (6) , 1458-1468
Intermediate outcomes of SIBS microshunt in cases of refractory and nonrefractory glaucoma
- 7 September 2026
- Published by Elsevier in Canadian Journal of Ophthalmology
- Vol. 61 (6) , 1458-1468
Open AccessIntermediate outcomes of SIBS microshunt in cases of refractory and nonrefractory glaucoma
- Open Access
- 1 September 2026
- Published by Taylor & Francis in Clinical Ophthalmology
- Vol. ume 20, 1-17
XEN63 Gel Stent in Glaucoma: Narrative Review and Expert Perspectives on Patient Selection, Surgical Technique, and Perioperative Management
The XEN gel stent (AbbVie Inc. North Chicago, IL, USA) is a minimally invasive bleb-forming surgical device designed to lower intraocular pressure (IOP). The 63 μm gel stent has a larger lumen than the 45 μm gel stent, creating lower outflow resistance, which may translate into greater IOP-lowering potential. However, the comparative evidence base remains limited, heterogeneous, and largely retrospective; the magnitude and durability of any advantage over the 45 μm device should be interpreted cautiously. This narrative review summarizes the currently available evidence and expert surgical perspectives on patient selection, pre- and intraoperative practices, implantation technique, and postoperative practices with the 63 μm gel implant. Particular attention is given to conjunctival and Tenon’s tissue management, use of mitomycin C (MMC), management of postoperative IOP elevation, and recognition and treatment of hypotony. The article is based on a targeted review of the literature combined with unstructured expert input and was not conducted as a systematic review or formal Delphi consensus. Based on the available evidence and expert perspectives, the 63 μm gel stent may be a useful option for selected patients requiring IOP in the low- to mid-teens. However, outcomes depend heavily on patient factors, surgical technique, and postoperative care.
- 1 September 2026
- Published by Taylor & Francis in Clinical Ophthalmology
- Vol. ume 20, 1-17
Open AccessXEN63 Gel Stent in Glaucoma: Narrative Review and Expert Perspectives on Patient Selection, Surgical Technique, and Perioperative Management
The XEN gel stent (AbbVie Inc. North Chicago, IL, USA) is a minimally invasive bleb-forming surgical device designed to lower intraocular pressure (IOP). The 63 μm gel stent has a larger lumen than the 45 μm gel stent, creating lower outflow resistance, which may translate into greater IOP-lowering potential. However, the comparative evidence base remains limited, heterogeneous, and largely retrospective; the magnitude and durability of any advantage over the 45 μm device should be interpreted cautiously. This narrative review summarizes the currently available evidence and expert surgical perspectives on patient selection, pre- and intraoperative practices, implantation technique, and postoperative practices with the 63 μm gel implant. Particular attention is given to conjunctival and Tenon’s tissue management, use of mitomycin C (MMC), management of postoperative IOP elevation, and recognition and treatment of hypotony. The article is based on a targeted review of the literature combined with unstructured expert input and was not conducted as a systematic review or formal Delphi consensus. Based on the available evidence and expert perspectives, the 63 μm gel stent may be a useful option for selected patients requiring IOP in the low- to mid-teens. However, outcomes depend heavily on patient factors, surgical technique, and postoperative care.
- Open Access
- 17 August 2026
- Published by Elsevier in Ophthalmology Glaucoma
Three-Year Treatment Outcomes of Ahmed Glaucoma Valve Implantation with Adjunctive Intraoperative and Postoperative Mitomycin C
- 17 August 2026
- Published by Elsevier in Ophthalmology Glaucoma
Open AccessThree-Year Treatment Outcomes of Ahmed Glaucoma Valve Implantation with Adjunctive Intraoperative and Postoperative Mitomycin C
- Open Access
- 1 August 2026
- Published by Taylor & Francis in Clinical Ophthalmology
- Vol. ume 20, 1-14
Peripheral Iris Cerclage in Angle Closure Glaucoma: A Retrospective Pilot Study
Purpose: To describe a novel surgical technique using peripheral iris cerclage (PIC) and evaluate clinical and anatomical outcomes in eyes with angle-closure glaucoma (ACG). Methods: Single-center retrospective pilot study of 8 consecutive eyes (7 patients) with ACG at high risk of recurrence undergoing peripheral iris cerclage (2010– 2025), with adjunctive procedures. Primary outcomes were postoperative Shaffer angle grade and peripheral anterior synechiae (PAS). Secondary outcomes included surgical success, intraocular pressure (IOP), and glaucoma medication use. Surgical success was defined as IOP ≤ 18 mmHg with ≥ 20% reduction from baseline, without clinical hypotony (IOP < 6 mmHg accompanied by ≥ 2-line loss of visual acuity from baseline). Eyes that underwent surgical revision, reoperation or developed no light perception vision were classified as failures. Complete success required no glaucoma medications; qualified success permitted glaucoma medications. Results: Median Shaffer angle grading (interquartile range [IQR]) increased significantly from 0 (0– 0) to 3 (3– 3) (P=0.01), and PAS also significantly decreased in all eyes (P=0.03), with 6 eyes (75%) demonstrating no PAS. Postoperative imaging demonstrated relative thinning of the peripheral iris and widening of the angle. Median IOP decreased from 33.5 (31.2– 43.5) mmHg to 12.0 (10– 15) mmHg (p=0.01) and medication classes decreased from 4 (4– 4) to 2 (1– 3) (p=0.04). Two eyes (25.0%) achieved complete success, while 7 eyes (87.5%) achieved qualified success. No intraoperative complications occurred. One patient required secondary glaucoma surgery. Conclusion: Peripheral iris cerclage was associated with sustained angle widening, favorable PAS outcomes, and substantial IOP reduction in this pilot series. This technique may serve as a useful adjunct in the surgical management of glaucoma, particularly in ACG eyes with flaccid iris tone, a high or thick iris insertion, and risk of recurrent synechiae.
- 1 August 2026
- Published by Taylor & Francis in Clinical Ophthalmology
- Vol. ume 20, 1-14
Open AccessPeripheral Iris Cerclage in Angle Closure Glaucoma: A Retrospective Pilot Study
Purpose: To describe a novel surgical technique using peripheral iris cerclage (PIC) and evaluate clinical and anatomical outcomes in eyes with angle-closure glaucoma (ACG). Methods: Single-center retrospective pilot study of 8 consecutive eyes (7 patients) with ACG at high risk of recurrence undergoing peripheral iris cerclage (2010– 2025), with adjunctive procedures. Primary outcomes were postoperative Shaffer angle grade and peripheral anterior synechiae (PAS). Secondary outcomes included surgical success, intraocular pressure (IOP), and glaucoma medication use. Surgical success was defined as IOP ≤ 18 mmHg with ≥ 20% reduction from baseline, without clinical hypotony (IOP < 6 mmHg accompanied by ≥ 2-line loss of visual acuity from baseline). Eyes that underwent surgical revision, reoperation or developed no light perception vision were classified as failures. Complete success required no glaucoma medications; qualified success permitted glaucoma medications. Results: Median Shaffer angle grading (interquartile range [IQR]) increased significantly from 0 (0– 0) to 3 (3– 3) (P=0.01), and PAS also significantly decreased in all eyes (P=0.03), with 6 eyes (75%) demonstrating no PAS. Postoperative imaging demonstrated relative thinning of the peripheral iris and widening of the angle. Median IOP decreased from 33.5 (31.2– 43.5) mmHg to 12.0 (10– 15) mmHg (p=0.01) and medication classes decreased from 4 (4– 4) to 2 (1– 3) (p=0.04). Two eyes (25.0%) achieved complete success, while 7 eyes (87.5%) achieved qualified success. No intraoperative complications occurred. One patient required secondary glaucoma surgery. Conclusion: Peripheral iris cerclage was associated with sustained angle widening, favorable PAS outcomes, and substantial IOP reduction in this pilot series. This technique may serve as a useful adjunct in the surgical management of glaucoma, particularly in ACG eyes with flaccid iris tone, a high or thick iris insertion, and risk of recurrent synechiae.
- Open Access
- 1 July 2026
- Published by Taylor & Francis in Clinical Ophthalmology
- Vol. ume 20, 1-14
Visual and Patient-Reported Outcomes of a Non-Diffractive Extended Depth-of-Focus Intraocular Lens with Micro-Monovision in Eyes with Early Macular Pathology
To evaluate visual and patient-reported outcomes after bilateral implantation of a non-diffractive extended depth of focus (EDOF) IOL (AcrySof IQ Vivity, Alcon) in patients with early macular pathology. Single-site, prospective, non-comparative pilot cohort study. The study included 20 patients (40 eyes) undergoing bilateral cataract surgery with at least one eye with early-stage macular pathology, specifically age-related macular degeneration (AREDS category 2) or epiretinal membrane (stage 0). All patients received bilateral implantation of the non-diffractive EDOF IOL targeted for micro-monovision. Primary outcomes were monocular corrected distance visual acuity (CDVA) and distance-corrected intermediate visual acuity (DCIVA) at 3 months. Secondary outcomes included binocular CDVA, DCIVA, and distance-corrected near visual acuity (DCNVA); uncorrected distance, intermediate and near visual acuity (UDVA, UIVA, UNVA); refractive outcomes; contrast sensitivity and patient-reported outcomes, including satisfaction and visual disturbances. At 3 months, median (IQR) monocular CDVA, DCIVA, and DCNVA were 0.00 (0.00-0.10), 0.18 (0.08-0.28), and 0.40 (0.30-0.50) logMAR, respectively. Binocular CDVA, DCIVA, and DCNVA were 0.00 (0.00-0.00), 0.13 (0.08-0.18), and 0.35 (0.22-0.40). Binocular UDVA, UIVA, and UNVA were 0.00 (0.00-0.00), 0.08 (-0.01-0.11), and 0.30 (0.20-0.33) logMAR, respectively. 90% of dominant and 95% of non-dominant eyes were within ±0.50 D of the intended outcome. Photopic contrast sensitivity was within normal range, while mesopic values were near the lower end of normal. Most patients (90%) were satisfied with their vision. Visual disturbances were low in frequency, severity, and bothersomeness, with median Rasch-calibrated scores of 32, 27, and 29, respectively. In patients with early macular pathology, bilateral implantation of a non-diffractive EDOF IOL demonstrated promising distance and intermediate vision, favorable near visual outcomes, and high patient satisfaction with minimal visual disturbances. Larger, prospective, comparative studies are warranted to define candidacy for patients with macular pathology.
- 1 July 2026
- Published by Taylor & Francis in Clinical Ophthalmology
- Vol. ume 20, 1-14
Open AccessVisual and Patient-Reported Outcomes of a Non-Diffractive Extended Depth-of-Focus Intraocular Lens with Micro-Monovision in Eyes with Early Macular Pathology
To evaluate visual and patient-reported outcomes after bilateral implantation of a non-diffractive extended depth of focus (EDOF) IOL (AcrySof IQ Vivity, Alcon) in patients with early macular pathology. Single-site, prospective, non-comparative pilot cohort study. The study included 20 patients (40 eyes) undergoing bilateral cataract surgery with at least one eye with early-stage macular pathology, specifically age-related macular degeneration (AREDS category 2) or epiretinal membrane (stage 0). All patients received bilateral implantation of the non-diffractive EDOF IOL targeted for micro-monovision. Primary outcomes were monocular corrected distance visual acuity (CDVA) and distance-corrected intermediate visual acuity (DCIVA) at 3 months. Secondary outcomes included binocular CDVA, DCIVA, and distance-corrected near visual acuity (DCNVA); uncorrected distance, intermediate and near visual acuity (UDVA, UIVA, UNVA); refractive outcomes; contrast sensitivity and patient-reported outcomes, including satisfaction and visual disturbances. At 3 months, median (IQR) monocular CDVA, DCIVA, and DCNVA were 0.00 (0.00-0.10), 0.18 (0.08-0.28), and 0.40 (0.30-0.50) logMAR, respectively. Binocular CDVA, DCIVA, and DCNVA were 0.00 (0.00-0.00), 0.13 (0.08-0.18), and 0.35 (0.22-0.40). Binocular UDVA, UIVA, and UNVA were 0.00 (0.00-0.00), 0.08 (-0.01-0.11), and 0.30 (0.20-0.33) logMAR, respectively. 90% of dominant and 95% of non-dominant eyes were within ±0.50 D of the intended outcome. Photopic contrast sensitivity was within normal range, while mesopic values were near the lower end of normal. Most patients (90%) were satisfied with their vision. Visual disturbances were low in frequency, severity, and bothersomeness, with median Rasch-calibrated scores of 32, 27, and 29, respectively. In patients with early macular pathology, bilateral implantation of a non-diffractive EDOF IOL demonstrated promising distance and intermediate vision, favorable near visual outcomes, and high patient satisfaction with minimal visual disturbances. Larger, prospective, comparative studies are warranted to define candidacy for patients with macular pathology.
- 19 June 2026
Evaluation of the Deep Reality Viewer for teaching slit lamp examination of the anterior segment and the optic nerve head.
A major challenge in teaching slit-lamp biomicroscopy is providing adequate depth perception and anatomical detail; the Deep Reality Viewer (DRV) addresses this by enabling stereopsis. This study evaluated the utility of DRV for slit-lamp examination (SLE) teaching and compared it with 2-dimensional monitors. In this single-centre prospective comparative study, 33 medical learners completed a qualitative assessment comparing DRV versus 2-dimensional (2D) monitors for SLE of the anterior segment and optic nerve head (ONH). Perceived educational value and task-specific utility were compared across 16 Likert-scale (1-5) parameters in 4 domains: image quality, anatomical visualization, user experience, and teaching utility. The primary outcome was the comparison of teaching utility ratings between modalities. Secondary outcomes included composite domain scores, trainee-level differences, and intermodality agreement for ONH assessments. Median [IQR] DRV was rated significantly higher than 2D monitors for image quality (4.3 [4.0-4.6] vs 3.5 [3.3-4.2]; p < .001), anatomical visualization (4.4 [4.0-4.8] vs 3.6 [3.2-4.3]; p < .001), and teaching utility (5.0 [4.5-5.0] vs 4.0 [3.8-4.8]; p < .001). Cup-to-disc ratio estimates showed minimal systematic bias (mean differences -0.01 to 0.03) with no significant difference in variability between DRV and 2D monitors (all p > .05). Subjective ratings of ONH visual quality did not significantly differ between modalities (all p > .05). DRV may be a useful tool to improve SLE teaching, as its perceived image quality and depth perception appear superior to 2D monitors.
- 19 June 2026
Evaluation of the Deep Reality Viewer for teaching slit lamp examination of the anterior segment and the optic nerve head.
A major challenge in teaching slit-lamp biomicroscopy is providing adequate depth perception and anatomical detail; the Deep Reality Viewer (DRV) addresses this by enabling stereopsis. This study evaluated the utility of DRV for slit-lamp examination (SLE) teaching and compared it with 2-dimensional monitors. In this single-centre prospective comparative study, 33 medical learners completed a qualitative assessment comparing DRV versus 2-dimensional (2D) monitors for SLE of the anterior segment and optic nerve head (ONH). Perceived educational value and task-specific utility were compared across 16 Likert-scale (1-5) parameters in 4 domains: image quality, anatomical visualization, user experience, and teaching utility. The primary outcome was the comparison of teaching utility ratings between modalities. Secondary outcomes included composite domain scores, trainee-level differences, and intermodality agreement for ONH assessments. Median [IQR] DRV was rated significantly higher than 2D monitors for image quality (4.3 [4.0-4.6] vs 3.5 [3.3-4.2]; p < .001), anatomical visualization (4.4 [4.0-4.8] vs 3.6 [3.2-4.3]; p < .001), and teaching utility (5.0 [4.5-5.0] vs 4.0 [3.8-4.8]; p < .001). Cup-to-disc ratio estimates showed minimal systematic bias (mean differences -0.01 to 0.03) with no significant difference in variability between DRV and 2D monitors (all p > .05). Subjective ratings of ONH visual quality did not significantly differ between modalities (all p > .05). DRV may be a useful tool to improve SLE teaching, as its perceived image quality and depth perception appear superior to 2D monitors.
- Open Access
- 1 June 2026
- Published by Taylor & Francis in Clinical Ophthalmology
- Vol. ume 20, 1-16
Comparative Outcomes of Standalone Xen63 Gel Stent and Preserflo Microshunt Implantation: A Multicenter Study
Purpose: To evaluate the intraocular pressure (IOP)-lowering efficacy and adverse event profile of Xen63 gel stent compared to the Preserflo microshunt. Methods: Retrospective, multicenter, two-arm cohort study comparing 65 eyes undergoing standalone Xen63 implantation and 75 eyes undergoing standalone Preserflo implantation, all with intraoperative mitomycin C (MMC). Primary outcome was complete success, defined as all of the followings: 1) no two consecutive IOP readings > 17mmHg, 2) ≥ 20% IOP reduction from baseline; 3) no clinical hypotony (IOP < 6 mmHg associated with loss of ≥ 2 lines of vision); and 4) no use of glaucoma medications. Secondary outcomes included success at different IOP cut offs, qualified success (allowing medications), change in IOP, medications, complications, interventions, and re-operations. Results: At 12 months, complete success was achieved in 61.5% of eyes in the Xen63 group and 73.9% in the Preserflo group (p = 0.13). Postoperative complications were more frequent in the Xen63 group compared with the Preserflo group (61.5% vs. 29.3%, p = 0.0002). Postoperative interventions were required at similar rates between groups (Xen63 30.8% vs. Preserflo 28.0%, p = 0.85); however, reoperations were performed more frequently in the Xen63 group (16.9% vs. 4.0%, p = 0.01). Non-Caucasian ethnicity was associated with an increased risk of surgical failure (HR 2.57; 95% CI, 1.26– 5.23). Conclusion: Both devices achieved comparable success rates, median IOP reduction, and postoperative medication burden; however, the Xen63 group experienced a higher rate of complications and reoperations.
- 1 June 2026
- Published by Taylor & Francis in Clinical Ophthalmology
- Vol. ume 20, 1-16
Open AccessComparative Outcomes of Standalone Xen63 Gel Stent and Preserflo Microshunt Implantation: A Multicenter Study
Purpose: To evaluate the intraocular pressure (IOP)-lowering efficacy and adverse event profile of Xen63 gel stent compared to the Preserflo microshunt. Methods: Retrospective, multicenter, two-arm cohort study comparing 65 eyes undergoing standalone Xen63 implantation and 75 eyes undergoing standalone Preserflo implantation, all with intraoperative mitomycin C (MMC). Primary outcome was complete success, defined as all of the followings: 1) no two consecutive IOP readings > 17mmHg, 2) ≥ 20% IOP reduction from baseline; 3) no clinical hypotony (IOP < 6 mmHg associated with loss of ≥ 2 lines of vision); and 4) no use of glaucoma medications. Secondary outcomes included success at different IOP cut offs, qualified success (allowing medications), change in IOP, medications, complications, interventions, and re-operations. Results: At 12 months, complete success was achieved in 61.5% of eyes in the Xen63 group and 73.9% in the Preserflo group (p = 0.13). Postoperative complications were more frequent in the Xen63 group compared with the Preserflo group (61.5% vs. 29.3%, p = 0.0002). Postoperative interventions were required at similar rates between groups (Xen63 30.8% vs. Preserflo 28.0%, p = 0.85); however, reoperations were performed more frequently in the Xen63 group (16.9% vs. 4.0%, p = 0.01). Non-Caucasian ethnicity was associated with an increased risk of surgical failure (HR 2.57; 95% CI, 1.26– 5.23). Conclusion: Both devices achieved comparable success rates, median IOP reduction, and postoperative medication burden; however, the Xen63 group experienced a higher rate of complications and reoperations.
- Open Access
- 1 April 2026
- Published by Taylor & Francis in Clinical Ophthalmology
- Vol. ume 20, 1-2
A Systematic and Narrative Review of Safety and Complications in Minimally Invasive Glaucoma Surgery (MIGS) Between 2014–2024 [Letter]
Introduction: Earlier intervention in glaucoma has been suggested to slow disease progression and preserve visual function and quality of life. Consequently, minimally invasive glaucoma surgery (MIGS) is increasingly used in mild-to-moderate glaucoma. Although numerous techniques and devices are available, their comparative efficacy remains debated: most procedures lower intraocular pressure to the mid-teens in primary open-angle glaucoma, but without clear evidence of superiority. As these surgeries are now offered to younger, otherwise healthy patients, safety has therefore become a central criterion in technique selection. Methods: This PRISMA-based systematic review analyzed safety outcomes from peer-reviewed studies of the main MIGS procedures published between 2014 and 2024. Five databases were searched using current and historical device names. Non-clinical studies, case series, and nonstandard techniques were excluded from quantitative analysis but retained qualitatively to capture rare events. A total of 401 studies, representing 39,381 eyes and 68,917 eye-years of follow-up, were included. Highest reported and weighted mean complication rates were calculated by procedure type. Results: Safety profiles varied. Trabecular bypass implants and ab interno canaloplasty were associated with low rates of serious adverse events and minimal anatomical disruption. Suprachoroidal devices carried higher risks of hypotony, inflammation, and malposition. Across all categories, chronic changes to angle anatomy and occasionnal re-interventions highlighted the potential for long-term sequelae, with endothelial cell loss emerging as a key concern for certain procedures.However, heterogeneity in definitions and reporting limited comparability. Common events such as hyphema and IOP spikes were inconsistently documented, while late complications like endothelial cell loss or peripheral anterior synechiae were often overlooked. This underreporting risks conflicting conclusions and undermines comparisons. Conclusion: For patients with mild, stable disease or those undergoing opportunistic combined surgery, tissue-sparing procedures with the lowest observed complication rates may be preferable. Standardized definitions, long-term follow-up, and harmonized safety reporting are becoming essential.
- 1 April 2026
- Published by Taylor & Francis in Clinical Ophthalmology
- Vol. ume 20, 1-2
Open AccessA Systematic and Narrative Review of Safety and Complications in Minimally Invasive Glaucoma Surgery (MIGS) Between 2014–2024 [Letter]
Introduction: Earlier intervention in glaucoma has been suggested to slow disease progression and preserve visual function and quality of life. Consequently, minimally invasive glaucoma surgery (MIGS) is increasingly used in mild-to-moderate glaucoma. Although numerous techniques and devices are available, their comparative efficacy remains debated: most procedures lower intraocular pressure to the mid-teens in primary open-angle glaucoma, but without clear evidence of superiority. As these surgeries are now offered to younger, otherwise healthy patients, safety has therefore become a central criterion in technique selection. Methods: This PRISMA-based systematic review analyzed safety outcomes from peer-reviewed studies of the main MIGS procedures published between 2014 and 2024. Five databases were searched using current and historical device names. Non-clinical studies, case series, and nonstandard techniques were excluded from quantitative analysis but retained qualitatively to capture rare events. A total of 401 studies, representing 39,381 eyes and 68,917 eye-years of follow-up, were included. Highest reported and weighted mean complication rates were calculated by procedure type. Results: Safety profiles varied. Trabecular bypass implants and ab interno canaloplasty were associated with low rates of serious adverse events and minimal anatomical disruption. Suprachoroidal devices carried higher risks of hypotony, inflammation, and malposition. Across all categories, chronic changes to angle anatomy and occasionnal re-interventions highlighted the potential for long-term sequelae, with endothelial cell loss emerging as a key concern for certain procedures.However, heterogeneity in definitions and reporting limited comparability. Common events such as hyphema and IOP spikes were inconsistently documented, while late complications like endothelial cell loss or peripheral anterior synechiae were often overlooked. This underreporting risks conflicting conclusions and undermines comparisons. Conclusion: For patients with mild, stable disease or those undergoing opportunistic combined surgery, tissue-sparing procedures with the lowest observed complication rates may be preferable. Standardized definitions, long-term follow-up, and harmonized safety reporting are becoming essential.